"July 22, 2015 -- New results from ongoing clinical trials have fueled hopes for a class of Alzheimer's drugs that target the buildup of sticky plaque in the brain linked to the disease.
The data, presented Wednesday to a standing-room-only "...
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In clinical studies, 555 patients were exposed to Amyvid. Amyvid caused no serious adverse reactions in the studies and the reported adverse reactions were predominantly mild to moderate in severity. The adverse reactions reported in more than one subject within the studies are shown in Table 2.
Table 2: Adverse Reactions
Reported in Clinical Trials (N=555 patients)
|Adverse Reactions||N (Percent of patients)|
|Musculoskeletal pain||4 (0.7%)|
|Blood pressure increaseda||4 (0.7%)|
|Injection site reactionb||3 (0.5%)|
|Back pain||2 (0.4%)|
|Feeling coldc||2 (0.4%)|
|Neck pain||2 (0.4%)|
|aIncludes the terms blood pressure increased and
bIncludes the terms injection site haemorrhage, injection site irritation, and injection site pain.
cIncludes the terms feeling cold and chills.
Other adverse reactions occurred at lower frequencies and included infusion site rash, dysgeusia, pruritis, urticaria, and flushing.
Read the Amyvid (florbetapir f 18 injection) Side Effects Center for a complete guide to possible side effects
Pharmacodynamic drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Amyvid image results.
Within a clinical study of patients with a range of cognitive impairment, some patients with probable AD were receiving the following medications: donepezil, galantamine, memantine. Mean cortical Standardized Uptake Value (SUV) ratios did not differ between the patients taking or not taking these concomitant medications. In in vitro tests, none of the drugs tested, including the acetylcholinesterase inhibitors donepezil, galantamine, and tacrine, altered florbetapir F 18 binding to its target.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/23/2014
Additional Amyvid Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.